Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

Evidence and Design

The study genotyped 700 unrelated women with fibromyalgia for FMR1 CGG repeat expansions and identified 3 premutation carriers (0.4%), rates consistent with the general female population (1/250–1/400; P = 0.539 and P = 0.716). All 3 carriers showed prominent neurological features — muscular symptoms, neurocognitive alterations, and neurovegetative impairment — but were otherwise clinically indistinguishable from typical fibromyalgia patients. The authors conclude that FMR1 screening should not be incorporated into routine rheumatologic workup, while suggesting stratification of fibromyalgia presentations by carrier status Fibromyalgia FMR1 screening cohort.

This null result directly contextualizes the earlier observation that fibromyalgia was reported in 43.8% of female premutation carriers with FXTAS versus 8.3% of non-FXTAS carriers and 9.4% of controls (P = 0.0097) FXTAS carrier comorbidity survey — an association likely inflated by self-referral of symptomatic women to fragile X clinics. The 2012 screening therefore tests the reverse direction (carrier frequency among unselected fibromyalgia patients) and finds no enrichment.

Critical caveats: the fibromyalgia cohort lacked an age- and ethnicity-matched control cohort genotyped in parallel; P-values are computed against literature-based population rates rather than an internal control. Three carriers is too few to characterize phenotype differences, and the reported neurological symptoms in carriers could reflect ascertainment (detailed neurologic exam applied only to carriers). The population-rate estimates themselves carry uncertainty, though the observed 0.4% sits comfortably within the plausible 0.25–0.40% range, so the null conclusion is reasonable. Confidence: moderate — well-powered for a modest enrichment (would have detected ~3-fold excess), but phenotype subtyping is underpowered.

 BGPT Paper Review

Study Novelty

Directly tests a hypothesis already raised by the 2008 expanded-phenotype study; the reverse-direction screening is a modest but timely extension, not a conceptual breakthrough.

Scientific Quality

Adequate sample size (n=700) and straightforward molecular methods, but no internal control cohort, only 3 carriers, and phenotype comparisons are anecdotal; P-values rely on external population estimates.

Study Generality

Findings are specific to fibromyalgia and the FMR1 locus; the negative screening result has limited broader mechanistic value.

Study Usefulness

Practically useful for clinicians: discourages routine FMR1 testing in fibromyalgia while flagging neurological symptoms as a possible stratum for selective testing.

Study Reproducibility

PCR-based CGG repeat genotyping is standard and reproducible; recruitment criteria and cohort sourcing are described at a level permitting replication.

Explanatory Depth

Purely associative screening with no mechanistic investigation of why carriers, if any, might present differently; the neurological-phenotype observation is descriptive.